Navigation Links
Statement from the American College of Surgeons Regarding Recent Comments from President Obama
Date:8/12/2009

CHICAGO, Aug. 12 /PRNewswire-USNewswire/ -- The American College of Surgeons is deeply disturbed over the uninformed public comments President Obama continues to make about the high-quality care provided by surgeons in the United States. When the President makes statements that are incorrect or not based in fact, we think he does a disservice to the American people at a time when they want clear, understandable facts about health care reform. We want to set the record straight.

  • Yesterday during a town hall meeting, President Obama got his facts completely wrong. He stated that a surgeon gets paid $50,000 for a leg amputation when, in fact, Medicare pays a surgeon between $740 and $1,140 for a leg amputation. This payment also includes the evaluation of the patient on the day of the operation plus patient follow-up care that is provided for 90 days after the operation. Private insurers pay some variation of the Medicare reimbursement for this service.
  • Three weeks ago, the President suggested that a surgeon's decision to remove a child's tonsils is based on the desire to make a lot of money. That remark was ill-informed and dangerous, and we were dismayed by this characterization of the work surgeons do. Surgeons make decisions about recommending operations based on what's right for the patient.

We agree with the President that the best thing for patients with diabetes is to manage the disease proactively to avoid the bad consequences that can occur, including blindness, stroke, and amputation. But as is the case for a person who has been treated for cancer and still needs to have a tumor removed, or a person who is in a terrible car crash and needs access to a trauma surgeon, there are times when even a perfectly managed diabetic patient needs a surgeon. The President's remarks are truly alarming and run the risk of damaging the all-important trust bet
'/>"/>

SOURCE American College of Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ConvaTec Launches Versiva(R) XC(R) Campaign and Best Practice Statement
2. Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
3. Pelosi Statement on Energy and Commerce Committee Passage of Health Insurance Reform Legislation
4. Health Care Statement of Catholic Charities USA
5. Statement by Jim OHara, Director, Produce Safety Project, in Response to the FDAs Announcement Regarding Guidance on Produce Safety
6. Pew Statement on House Passage of Food Safety Legislation
7. Video: American Dental Association Statement: Food and Drug Administration Action on Dental Amalgam
8. CareFusion Form 10 Registration Statement Declared Effective
9. Pelosi Statement on House Passage of Labor, HHS, Appropriations Bill, Which Lifts Ban on Needle Exchange
10. Statement By Dr. Paul Zeitz Regarding a Proposed Amendment By Rep. Mark Souder to Prohibit HHS Funding For Needle Exchange
11. Change to Win Statement on Minimum Wage Increase
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Authentidate Holding Corp. Completes Capital Raise 2Health News:Authentidate Holding Corp. Completes Capital Raise 3Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 2Health News:Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange 3Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 2Health News:UPMC Health Plan Offers Brain Fitness Software to Improve Health 3Health News:New research identifies modifiable risk factors for heart disease 2Health News:New research identifies modifiable risk factors for heart disease 3Health News:New research identifies modifiable risk factors for heart disease 4Health News:New research identifies modifiable risk factors for heart disease 5Health News:New research identifies modifiable risk factors for heart disease 6Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 2Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 3Health News:National Oncologist Group Warns: Current Health Care Reform Legislation Woefully Short In Addressing Cancer Care Crisis 4
Breaking Medicine Technology:AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Negative Pressure Wound Devices Draw FDA Notice, Advice 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Photo 3A Poor Disabled Children in Ecuador Receive Free Wheelchairs 21 56135 1Photo 3A Poor Disabled Children in Ecuador Receive Free Wheelchairs 21 56135 2Photo 3A Poor Disabled Children in Ecuador Receive Free Wheelchairs 21 56135 3Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility 56131 1Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility 56131 2Regado Biosciences to Present at the Rodman 26 Renshaw Global Investment Conference on September 10 2009 13829 1Regado Biosciences to Present at the Rodman 26 Renshaw Global Investment Conference on September 10 2009 13829 2
Other Medicine Technology:Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 2OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 3OncoGenex Technologies Announces Phase II Data of OGX-011 in,Metastatic Breast Cancer at American Association for Cancer,Research 2007 Annual Meeting 4